Efficacy of BNG-1 to Treat Acute Ischemic Stroke

Ischemic Stroke Clinical Trial

— BNG-1  

Official title:

A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Compare the Functional Outcome and Safety of Treatment With BNG-1 in Combination With Aspirin With That of Aspirin Alone in Ischemic Stroke Recovery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01675115
• Other study ID #: BNG-1-PIIIB
• Status: Completed
• Phase: Phase 3
• First received: April 2, 2012
• Last updated: July 27, 2015
• Start date: August 2012
• Est. completion date: November 2014

Study information

• Verified date: July 2015
• Source: Chang Gung Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to investigate the efficacy and safety of BNG-1 in patients with ischemic stroke. The efficacy assessment will be based on the functional outcome while the safety will be reviewed by the adverse events and laboratory examinations.

Description:

The primary endpoint will be performed on the 12 weeks after study drug administered and will compare the favorable rate between treatment with Aspirin alone and combination treatment with BNG-1 and Aspirin in patients with ischemic stroke. The favorable to therapy will be determined if all of the following occurs: alive, Modified Rankin Scale (MRS) < 3, Barthel Index (BI) >= 60.

Secondary objectives are to compare the following:

1. Compare the favorable rate at one week after study drug administered and the end of treatment (Week 4) and 4 weeks of follow-up (Week 8) of either Aspirin alone or combination treatment with BNG-1 and Aspirin.

2. Compare the mean change in Barthel Index (BI), at each evaluation time-point of either Aspirin alone or combination treatment with BNG-1 and Aspirin.

3. Compare the mean change in National Institute of Health Stroke Scale (NIHSS) at each evaluation time-point of either Aspirin alone or combination treatment with BNG-1 and Aspirin.

4. Compare the Modified Rankin Scale (MRS) at each evaluation time-point of either Aspirin alone or combination treatment with BNG-1 and Aspirin.

5. Compare the change in Extended Glasgow Outcome Scale (GOS-E) at each evaluation time-point of either Aspirin alone or combination treatment with BNG-1 and Aspirin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 129
• Est. completion date: November 2014
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Both genders and ages 20 through 65 (subjects are at least 20 years old but not yet 66).

2. Clinical diagnosis of ischemic stroke, causing a measurable neurological deficit.

3. Onset of symptoms of ischemic stroke within 10 days of initiation of treatment with the study drug.

4. Patients have a total National Institutes of Health Stroke Scale (NIHSS) between 8 and 22 inclusive by the time of randomization.

5. Patients have a total Barth Index (BI) less than 60 or Modified Rankin Scale (MRS) at least 3 by the time of randomization.

6. No previous history of stroke or previous stroke with Modified Rankin Scale < 1.

7. Patient must have a CT or MRI examination compatible with the clinical diagnosis of acute ischemic stroke.

8. Signed informed consent from patient or legally authorized representative.

Exclusion Criteria:

1. Patient has only major symptoms that are rapidly improving by the time of randomization.

2. History of stroke within the previous 3 months, exclude TIA.

3. Patient has a CT or MRI scan with evidence of a non-ischemic mechanism, subarachnoid hemorrhage, primary intracerebral or intraventricular hemorrhage.

4. Patients with known or suspected prior intracranial haemorrhage or history of brain injury or brain tumor.

5. Patient had documented history of any atrial fibrillation occurring 6 months before randomization.

6. Hypertension, defined as systolic blood pressure > 185 mmHg or diastolic blood pressure >110 mmHg or requiring aggressive (eg, intravenous antihypertensive) treatment to reduce blood pressure to within these limits.

7. Recurrent peptic ulcer or gastrointestinal bleeding documented by radiographic or endoscopic means within the past 3 months.

8. Pregnant or lactating women or women of childbearing potential who are not practicing reliable birth control.

9. Platelet count less than 100,000 cells/ml.

10. Activated partial thromboplastin time (aPTT) prolongation greater than 2 seconds above the upper limit of normal for local laboratory.

11. International normalized ratio (INR) greater than or equal to 1.4.

12. Uncontrolled hyperglycemia (Sugar AC > 200 mg/dl).

13. History of alcohol or drug abuse in the previous 3 months.

14. History of hypersensitivity or intolerance of study drug or aspirin.

15. Neurological (other than the presenting stroke) or psychiatric conditions that may affect the patient's functional status and/or that may interfere with the patient's assessment.

16. Previously in the BRAIN-Study or participation in a research protocol for investigation of a pharmaceutical agent or innovative invasive procedure within the past 30 days.

17. Any other known clinically significant medical disorder (e.g., a severe comorbid disease or dementia, transient cerebral ischemia, lower gastrointestinal bleeding, bleeding diathesis, hepatorenal diseases, cancer, and AIDS).

18. Patients who have received anticoagulant agents, antiplatelet agents (except Aspirin), thrombolytics with 48-hour before randomization.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Drug:
• BNG-1
BNG-1 3 grams TID for 4 weeks
• Aspirin
Aspirin 100 mg QD for 4 weeks

Locations

Country	Name	City	State
Taiwan	Stroke center, Department of Neurology, Linkou Chang Gung Memorial Hospital	Kweishan	Taoyuan

Sponsors (1)

Lead Sponsor	Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Favorable rate	Favorite rate: A composite of mortality (alive), modified Rankin Scale < 3, AND Barthel Index (BI)>=60	12 weeks	No
Secondary	Favorable rate		12 weeks	No
Secondary	Barthel index		12 weeks	No
Secondary	Modified Rankin Scale		12 weeks	No
Secondary	National Institute of Health Stroke Scale		12 weeks	No
Secondary	Extended Glasgow Outcome Scale		12 weeks	No